clinical trial · NCT06053658
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center·phase2·recruiting·n = 48
Renal Cell CarcinomaTivozanibNivolumab
brief summary
To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.
started
Jan 5, 2024
primary completion
Nov 1, 2026
completion
Nov 1, 2028
last updated
Apr 14, 2026
detailed description
Primary Objectives
* To demonstrate efficacy of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (nccRCC).
Secondary Objectives
* To assess the safety and toxicity of combination tivozanib and nivolumab. * To estimate the duration of clinical efficacy
Exploratory Objectives
* To associate immune and tumor biomarkers with clinical efficacy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol